July 2020 – Proactive Investors: ReNeuron’s Michael Hunt says key focus now is to build dataset for retinal disease study
June 2020 – Proactive Investors: ReNeuron’s Michael Hunt explains new emphasis on its retinal and exosome technology programmes
June 2020 – Proactive Investors: One2One Virtual Event
11 June 2020: ReNeuron Group’s (LON:RENE) Michael Hunt pitches the company to investors at the Proactive One2One Virtual Event. The company’s a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
To view the link please CLICK HERE.
May 2020 – Proactive Investors: ReNeuron’s Michael Hunt talks new potential for its CTX therapy in treating Huntington’s disease
April 2020 – Proactive Investors: ReNeuron looking at applications of its own technology to deliver virus vaccine
February 2020 – Proactive Investors: ReNeuron’s retinal treatment ‘appears to have sustained long-term beneficial effect’
December 2019 – Proactive Investors: ReNeuron in active on-going talks for further potential out-licence deals
October 2019 – Proactive Investors: ‘All systems go’ for ReNeuron’s retinitis pigmentosa programme as it looks to follow-up studies
Proactive Investors: ReNeuron makes key business development hire as it looks to build on licensing deals
Proactive Investors: “ReNeuron ‘very encouraged’ by positive retinitis pigmentosa study results”